[Prevention of thrombosis with low molecular weight heparin as the only substance and/or with DHE: results of clinical studies].
In aspect of the high incidence of thrombosis and the resulting risk of fulminant pulmonary embolism and late complications, there is a demand for a general medical prophylaxis in operative medicine. A new chance to reduce the incidence of thrombosis is the recently developed low weight molecular heparine (LWMH). Current studies of different LWMH in general and thoracic surgery prove, that an effective decrease of thrombosis can be achieved with a single daily injection. Effectiveness of LWMH in high risk patients have not been sufficient evaluated yet in some of the used preparations.
Koppenhagen
K
K
Klinikum Steglitz FU Berlin.
Tröster
E
E
Matthes
M
M
Häring
R
R
D004087:Dihydroergotamine / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage*; D006801:Humans; D011183:Postoperative Complications / Q000517:prevention & control*; D011655:Pulmonary Embolism / Q000517:prevention & control*; D012307:Risk Factors; D013924:Thrombophlebitis / Q000517:prevention & control*
D006495:Heparin, Low-Molecular-Weight; D004087:Dihydroergotamine